Nuclear receptors PPARα

Česká verzia

Authors: V. Soška
Authors place of work: Centrum pro diagnostiku a léčbu dyslipidemií, Oddělení klinického komplementu FN u sv. Anny, Brno, přednosta doc. MUDr. Vladimír Soška, CSc.
Published in the journal: Vnitř Lék 2006; 52(6): 628-631
Category: Reviews

Summary

Mechanism of the fibrates action is mediated by nuclear PPARα receptors (Peroxisome Proliferator-Activated Receptor). These receptors regulate a number of genes that are involved both in lipids and lipoproteins metabolism and other mediators (e.g. inflammatory mediatores). Due to PPARα activation by fibrates, triglycerides and small dense LDL concentration is decreased, HDL cholesterol is increased and both inflammation and prothrombotic status are reduced. These effects are very important in patients with metabolic syndrom.

Key words:
nuclear receptors PPARα - fibrates - statins - metabolic syndrom

Zdroje

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-650.

2. Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000; 60: 1245-1250.

3. Jump DB, Botolin D, Wang Y et al. Fatty Acid regulation of hepatic gene transcription. J Nutr 2005; 135: 2503-2506.

4. Doška F. Thiazolidindiony - mechanismus účinku, užití v praxi a perspektivy. DMEV 2003: 4: 194-199.

5. Svačina Š. Nové perspektivy ovlivnění jaderných receptorů PPAR. Čas Lék Čes 2004; 143: 731-733.

6. Deng T, Shan S, Li ZB et al. New retinoid-like compound that activates peroxisome proliferator-activated receptors and lowers blood glucose in diabetic mice. Biol Pharm Bull 2005; 28: 1192-1196.

7. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 907-925.

8. Blanquart C, Barbier O, Fruchart JC et al. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 2003; 85: 267-273.

9. Fruchart JC, Staels B, Duriez P. New concepts on the mechanism of action of fibrates and therapeutic prospectives in atherosclerosis. Bull Acad Natl Med 2001; 185: 63-74.

10. Fruchart JC, Duriez P, Staels B. Molecular mechanism of action of the fibrates. J Soc Biol 1999; 193: 67-75.

11. Auwerx J, Schoonjans K, Fruchart JC et al. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. J Atheroscler Thromb 1996; 3: 81-89.

12. Auwerx J, Schoonjans K, Fruchart JC et al. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 1996; 124(Suppl): S29-S37.

13. Vu-Dac N, Schoonjans K, Kosykh V et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995; 96: 741-750.

14. von Eckardstein A, Hersberger M, Rohrer L. Current understanding of the metabolism and billogical actions of HDL. Curr Opin clin Nutr Metab Care 2005; 8: 147-152.

15. Lee JY, Parks JS. ATP-binding cassette transporter and its role in HDL formation. Curr Opin Lipidol 2005; 16: 19-25.

16. Wang N, Lan D, Chen W et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004; 101: 9774-9779.

17. Oram JF, Brinton EA, Bierman EL. Regulation of high density lipoprotein receptor activity in cultured human skin fibroblasts and human arterial smooth muscle cells. J Clin Invest 1983; 72: 1611-1621.

18. Trigatti BL, Krieger M, Rigotti H. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 1732-1738.

19. Okamoto H, Iwamoto T, Kotake S et al. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 323-330.

20. Delerive P, Martin-Nizard F, Chinetti G et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394-402.

21. Kleemann R, Gervois PP, Verschuren L et al. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 2003; 101: 545-551.

22. Soška V. Dyslipidémie a metabolický syndrom. Vnitř Lék 2003; 49: 943-947.

23. Han SH, Quon MJ, Koh KK. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 2005; 46: 1086-1092.

24. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497-505.

25. Fruchart JC, Duriez P. HMG CoA reductase inhibitors and PPAR-alpha activators: are their effects on high-density lipoprotein cholesterol and their pleiotropic effects clinically relevant in prevention trials? Curr Atheroscler Rep 2002; 4: 403-404.

26. Inoue I, Itoh F, Aoyagi S et al. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun 2002; 290: 131-139.

27. Vidal H. PPAR receptors: recent data. Ann Endocrinol (Paris) 2005; 66: 1S5-1S9.

28. Denning GM, Stoll LL. Peroxisome Proliferator-Activated Receptors: Potential Therapeutic Targets in Lung Disease? Pediatr Pulmonol 2005; 2: 145-149.

29. Brzozowski T, Konturek PC, Pajdo R et al. Agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma): a new compound with potent gastroprotective and ulcer healing properties. Inflammopharmacology 2005; 13: 317-330.

30. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005; 4: 193-205.

31. Halabi CM, Sigmund CD. Peroxisome Proliferator-Activated Receptor-gamma and its Agonists in Hypertension and Atherosclerosis : Mechanisms and Clinical Implications. Am J Cardiovasc Drugs 2005; 5: 389-398.

32. Rybka J. Current and future aspects of oral antidiabetic agents in type 2 diabetes. Vnitř Lék 2001; 47: 285-290.

33. Duval C, Chinetti G, Trottein F et al. The role of PPARs in atheroclerosis. Trends Mol Med 2002; 8: 422-430.